Clusters as a tool for Innovation at the University of Debrecen. Prof. Dr. József Tőzsér Deputy Rector, University of Debrecen

Transcription

1 Clusters as a tool for Innovation at the University of Debrecen Prof. Dr. József Tőzsér Deputy Rector, University of Debrecen

2 UD Facts and Figures Established: 1538 (1912) 14 faculties: medical and health sciences, agriculture, food and environmental sciences, arts, music, social sciences, natural sciences, ICT, engineering 7 campuses (5 in Debrecen, 1 in Nyíregyháza and 1 in Hajdúböszörmény) students > 5000 international students (17%) 1500 lecturers

3 Education 69 undergraduate programmes 81 graduate training programmes 6 single-cycle programmes 186 postgraduate specialist trainings 23 doctoral schools

4 Health Industry-related BSc/MSc degree programs at UD Clinical Research MSc -HU ( 25) Food Science MSc HU ( 20) Clinical Research BSc -HU ( 240) Molecular Biology MSc HU ( 50) Molecular Biology MSc - EN ( 20) Biotechnology MSc - HU ( 60) Biotechnology BSc - HU Biotechnology BSc -EN Bioengineer MSc - HU( 30) Bioengineer BSc HU ( 200) Bioengineer BSc - EN (8) 650 student + several single-cycle programs: MD (HU, EN), DPharm (HU, EN), Dentistry programs (HU, EN)

5 Programmes in English 60 accredited degree programmes running in English (Students from 109 countries) Single-cycle medical trainings Numerous undergraduate and graduate trainings: Engineering, IT and Natural Sciences Agricultural and Environmental Sciences Business, Management, Economics, Law

6 Research University University of National Excellence 2013 Talent management program TalentUD 6 spin-off companies focus areas: pharmaceutical research, food science, medical biology and sport sciences 23 doctoral schools in the following areas: o Arts and Humanities o Medical Sciences o Natural Sciences o Social Sciences o Agricultural Sciences

7 Health Industry and UD Hospital activities Medical and Dental treatments Other human health activities UN International Standard Industrial Classification Activities performed by UD Healthcare equipments Pharmaceuticals Biotechnology Related life sciences Global Industry Classification Standard Health science is in focus at UD Diverse, relevant training portfolio Industrial activities at UD Medical Isotope production

8 Biotechnology - UD Molecular diagnostics, omics, Biotechnolology-based therapies Cancer therapies Pharmaceutical biotechnology Industrial biotechnology Structure-function of metabolites Environmental biotechnology Animal and plant biotechnology Agromicrobiology, animal health Alfalfa protein expression Functional food

9 Health Pharmaceutical Industry Agriculture Wellness Inter-Cluster Network Burill & Company, A Life Sciences Merchant Bank; February 28, 2005

10 Structure of Cluster within the Pharmapolis Pole Industry Regional Government Cluster management Co (outside) Research Institution University, Academy Financial Insitutions -EU and HU governmental -Private capital 1. Building confidence among few people 2. Vision 3. Strategy: Common 4. Realization: Common Institutionization Among Cos Gidelines:The Cluster Policies Whitebook, IKED, 2004

11 Local Government Industry University Cooperation PHARMAPOLIS Services Pharma and Biotech Quality assurrance Education Research Functional food Herbal drugs New drugs Equipment and diagnostics Medical devices Research devices Diagnostics Health Health tourism Thermal tourism Re-evaluation of traditional medicine Others Conference tourism Hotel Wellness Others New Cos Venture capital, funds Regional industrial clusters, new clusterogenic externals PharmaIndustry Functional Food Industry Thermal and Health Industry

12 Accredited Clusters of Debrecen: Pharmapolis Clusters Pharmapolis Innovative Cluster of Pharmaceutical Industry Thermal Health Cluster Pharmapolis Functional Food Cluster Hungarian Cluster of Sports and Lifestyle Cluster of Informatics Local constitution of the Hungarian lead industrial branch concept at cluster formation level : Debrecen-Szeged-Balatonfüred Project Companies

13 Focus Areas of the Pharmapolis Innovative Cluster of Pharmaceutical Industry Innovative therapeutical products Formulation of Drug Candidates and Drugs Cell Therapy and Gene Therapy Functional Imaging Preclinical Imaging in the Pharmaceutical Industry Functional Imaging, Molecular Imaging In vitro technological platforms Biomarkers Laboratory Diagnostics Stress Protein-Based Drug Developement Education Biotechnology

14 Project pyramid Lead Oral insulin advanced Cicletanine (+) sulphoconjugate early Tinnitus generic Anti-obesity generic β3 agonist HISS cgmp-pde inhibitor targeted research HSP P2X7 TCM Cito- Anti- Diag. Cog MCH Pro Co-in prod stat. psyc sph Rmod kin.

15 Cluster Development through project companies, company networks and inter-cluster cooperations. Project Companies of the Pharmapolis Pharmaceutical Industry Cluster ( ) CERORIN Ltd. oral insulin Pharmatom Ltd. clinical safety pharmacology product Biodiagnosztika Ldt.. lung cancer diagnostics Parens Ltd. cell therapy Governmental participation Strategy Regional political support Infrastructure Project companies Co1 Co 2 Co 3 University Co 6 Regional Government Cluster Manager Co Co 5 Co4 Co77 Co 8 Co 9 Con n Banks Venture capital Private investors

16 Drug-food-health and wellness - within the same innovation chain Original drugs Innovative generics Biotechnology drugs Functional foods Health tourism services

17 Clinical development Drug candidates and follow-up molecules Lead determination Chemical hits ADME Tox.a Scale-up chemistry Computational modeling Chemical informatics Structure-effect relations Toxicology and safety pharmacology research Medicinal technology Natural baseline materials Combinatoric chemistry Chemical libraryr Chemical informatics The Hungarian Inter-Pole Cooperation in the Field of Pharmaceutical Industry organized along the innovation chain initiated by the University of Debrecen. (Agreement undersigned in ) Chemistry Expression arrays Bioinformatics EST Positional cloning Proteomics Cascade modelss Transgenics Knock-out Animal modelsl Disease modelingl Microarray Micro technology Robotics Dataction systems Genomics Functional genomics Target assessement Target identification High throughput screening

18 Research Harmonization drug targets Projects Integrated projects Service R&D QA CRO complex serv.

19 Risk Sharing Finance Structure in Cluster Networks Promoter Finance Model Project Finance Model Financing partners provide funding to the promoter on the basis of its project portfolio strength. The promoter role can be extended to a consortium of companies/institutions (university, hospital) The financing partners are thereby exposed to the credit risk of the promoter, not solely of the project. In the Project Finance Model, the project is realized and financed via a legally and financially standalone project company (SPV). The promoter(s) usually has the role of a strategic partner (e.g shareholder). The financing partners are thereby exposed to the credit risk of the project only. Source:

20 Thank you for your attention!